Tag: interim report

In the first half of 2025, revenue amounted to €7,115 thousand (H1 2024: €7,809 thousand). The decline was mainly due to a more competitive pricing strategy that was implemented on the Textmagic platform. EBITDA was €2,581 thousand (H1 2024: €3,149 thousand), and the operating loss totaled to €123 thousand (H1 2024: operating profit of €1,097 thousand). Profitability was negatively affected by an increase in amortization expenses of €652 thousand, resulting from the higher volume of development activities in previous periods with the goal of improving the value proposition.

In the second quarter, Tallinna Sadam earned close to 30 million euros in sales revenue and more than 3 million euros in profit. The revenue for six months was 58 million euros and the profit exceeded 10 million euros. In the second quarter, the volume of investments increased to 8 million euros, in the first half of the year we invested a total of 12 million euros.

Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy-Back Programme

MONTREAL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the second quarter of 2025.

Suominen Corporation’s Half-Year Financial Report on August 7, 2025, at 9:30 a.m. (EEST)

Suominen Corporation’s Half-Year Financial Report for January 1 – June 30, 2025:

ABN AMRO posts net profit of EUR 606 million in Q2 2025

eQ Plc stock exchange release
5 August 2025, at 8:15 a.m.

All amounts in U.S. dollars unless otherwise indicated

A webinar on the presentation of the results (in Estonian only) will take place on 31 July at 13:00 (EEST), more information.

Sales Revenues and Profitability

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI^®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.